Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.366 USD | -1.61% | -6.21% | -93.02% |
May. 07 | Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 | MT |
May. 07 | HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy | MT |
Financials (USD)
Sales 2024 * | 1.57M | Sales 2025 * | 672K | Capitalization | 22.68M |
---|---|---|---|---|---|
Net income 2024 * | -82M | Net income 2025 * | -75M | EV / Sales 2024 * | 14.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 33.7 x |
P/E ratio 2024 * |
-0.31
x | P/E ratio 2025 * |
-0.4
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.92% |
Latest transcript on Lyra Therapeutics, Inc.
1 day | +2.59% | ||
1 week | -11.43% | ||
Current month | -92.79% | ||
1 month | -92.95% | ||
3 months | -92.41% | ||
6 months | -87.08% | ||
Current year | -92.90% |
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 21-09-12 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 22-07-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 22-02-15 |
W. Smith
BRD | Director/Board Member | 68 | 19-11-18 |
James Tobin
BRD | Director/Board Member | 79 | 22-03-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 0.366 | -1.61% | 1 315 529 |
24-05-14 | 0.372 | +2.59% | 3,774,479 |
24-05-13 | 0.3626 | -2.66% | 2,592,227 |
24-05-10 | 0.3725 | -3.62% | 3,680,139 |
24-05-09 | 0.3865 | -0.85% | 5,265,060 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-92.90% | 22.68M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+47.07% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- LYRA Stock